Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Botulism Vaccine
Botulinum neurotoxin heavy chain fragments formulated for vaccine development
September 14th, 2005
Botulinum neurotoxin heavy chain fragments have been formulated for vaccine development. "Heavy chain fragments of botulinum neurotoxin serotypes A and B are being developed as a bivalent vaccine for botulism. To potentiate the immune response, an aluminum containing adjuvant will be formulated with the two antigens," scientists writing in the journal Vaccine report. "The adsorption mechanisms of each antigen to aluminum phosphate and aluminum hydroxide adjuvants were studied. The adsorption of the serotype A antigen to each adjuvant, and the serotype B antigen to aluminum phosphate adjuvant, is dependent on electrostatic attractive...
Source: Vaccine Weekly (2005-09-14)
|
